Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Krispy Kreme Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.22 (market cap $29.60B), while Krispy Kreme Inc trades at $3.16 (market cap $537.85M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 55× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DNUT | |
|---|---|---|
Market Cap | $29.60B | $537.85M |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $4.70 |
52-Week Low | $205.48 | $2.92 |
Enterprise Value | $27.56B | $1.78B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Krispy Kreme (DNUT) trades at $3.14, down 5.99% with bearish technical signals. The company shows mixed fundamentals with a high P/E ratio of 216.5 but attractive P/S of 0.36 and P/B of 0.87. Recent Q2 2026 earnings showed a narrowed loss of $0.03 per share, beating expectations, while revenue declined 12.8% due to refranchising. CEO Josh Charlesworth emphasized turnaround progress with margin improvement and deleveraging (Bloomberg, August 6, 2026).
The outlook remains challenging with negative net income margins and ROE, though analyst sentiment is cautiously optimistic with 50% buy ratings. Key risks include execution of the turnaround strategy and competitive pressures. The stock presents a speculative opportunity if management can sustain operational improvements and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
